2010/01/01 by Kenji Narushima, Laurie M. McCormick, Thoru Yamada +2 · 1 citation
Neuroscience · Psychology · Medicine · #Transcranial Magnetic Stimulation Studies #Obsessive-Compulsive Spectrum Disorders #Neurological disorders and treatments
paper · doi:10.1176/jnp.2010.22.1.75
openalex publication_date 2010/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for depression.Increased metabolism in the anterior cingulate cortex (ACC) is a known predictor for antidepressant response.The authors assessed whether increased theta power within the ACC predicts rTMS response in participants with vascular depression.Sixty-five participants were randomized to active or sham rTMS.Outcome was assessed using the Hamilton Depression Rating Scale.Electroencephalography was obtained, and comparisons were made among each group with a normative database using low-resolution electromagnetic tomography.Results suggest that vascular depression participants respond well to rTMS and that increased low-theta power in the subgenual ACC predicts response to rTMS.A modern apparatus of repetitive transcranial magnetic stimulation (rTMS) was developed in Great Britain in 1985. 1 Since then, rTMS has been utilized to provide noninvasive brain stimulation for research and treatment purposes.The most frequent application of rTMS in psychiatry has been as a treatment for major depression, and the first controlled treatment study was published in 1996. 2 Although a large number of studies have suggested that rTMS is efficacious against depression, a recent review found that the efficacy can be quite variable. 3This may be due to the fact that the etiological factors underlying major depression are heterogeneous, causing some forms of depression to respond better to rTMS than others.Repetitive transcranial magnetic stimulation has already been approved as a standard treatment procedure for depression in some countries such as Canada and Israel; however, it has only recently been approved by the Food and Drug Administration in the United States.The term "vascular depression" has been used to describe depression in elderly patients with cerebrovascular disease.A causal relationship between cerebrovascular disease and late-life depression is supported by evidence such as coexistence of depression with hypertension, coronary artery disease, and multiple hyperintensities on brain imaging. 4Patients with latelife depression often have a chronic, treatment resistant course and frequently meet criteria for vascular depression.